Rivastigmine metabolite
Based on 1 Customer Validation
Rivastigmine metabolite (NAP 226-90) is a metabolite produced by the hydrolysis of Rivastigmine (HY-17368). Rivastigmine metabolite serves as a surrogate marker to track the bioavailability, metabolic extent, and transdermal patch delivery rate of Rivastigmine.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.01%
- CAS 番号: 139306-10-8
- 分子式: C10H15NO
- 分子量:165.23
-
保管条件:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-W020576R
Rivastigmine metabolite (Standard)AChE Inhibitor -
HY-120553
B-355252NGF Receptor Agonist -
HY-124866
PDI-IN-3PDI Inhibitor -
HY-17552
sn-Glycero-3-phosphocholineCholinesterase (ChE) Activator -
HY-19948
Leucomethylene blue mesylateTau Aggregation Inhibitor -
HY-17552R
sn-Glycero-3-phosphocholine (Standard)Cholinesterase (ChE) Activator -
HY-113468
3-O-Methyl-DL-DOPAEndogenous Metabolite -
HY-113468R
3-O-Methyl-DL-DOPA (Standard)Endogenous Metabolite -
HY-134137
Donepezil N-oxideAChE Inhibitor -
HY-132392S
L-DOPA-2,5,6-d3Stable Isotope -
HY-107922
Ethopropazine hydrochlorideBChE/NMDA/mAChR Antagonist -
HY-W269511
NW-1689Process-related Impurity
生物活性
製品説明
体外実験
Rivastigmine metabolite is a metabolite produced by the hydrolysis of Rivastigmine[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 139306-10-8
-
性状 Solid
-
分子量 165.23
-
分子式 C10H15NO
-
Color White to off-white
-
SMILES
OC1=CC=CC([C@@H](N(C)C)C)=C1
-
別名
NAP 226-90
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶剤 & 溶解度
体外:
DMSO : ≥ 200 mg/mL (1210.43 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (30.26 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (30.26 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (271 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Polinsky RJ, et al. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998;20(4):634-647. [Content Brief]
[2]. Srinivas NR, et al. Transdermal Rivastigmine Delivery for Alzheimer Disease: Amenability of Exposure Predictions of Rivastigmine and Metabolite, NAP226-90, by Linear Regression Model Using Limited Samples. Clin Neuropharmacol. 2016;39(4):169-177. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.0522 mL | 30.2608 mL | 60.5217 mL | 151.3042 mL |
| 5 mM | 1.2104 mL | 6.0522 mL | 12.1043 mL | 30.2608 mL | |
| 10 mM | 0.6052 mL | 3.0261 mL | 6.0522 mL | 15.1304 mL | |
| 15 mM | 0.4035 mL | 2.0174 mL | 4.0348 mL | 10.0869 mL | |
| 20 mM | 0.3026 mL | 1.5130 mL | 3.0261 mL | 7.5652 mL | |
| 25 mM | 0.2421 mL | 1.2104 mL | 2.4209 mL | 6.0522 mL | |
| 30 mM | 0.2017 mL | 1.0087 mL | 2.0174 mL | 5.0435 mL | |
| 40 mM | 0.1513 mL | 0.7565 mL | 1.5130 mL | 3.7826 mL | |
| 50 mM | 0.1210 mL | 0.6052 mL | 1.2104 mL | 3.0261 mL | |
| 60 mM | 0.1009 mL | 0.5043 mL | 1.0087 mL | 2.5217 mL | |
| 80 mM | 0.0757 mL | 0.3783 mL | 0.7565 mL | 1.8913 mL | |
| 100 mM | 0.0605 mL | 0.3026 mL | 0.6052 mL | 1.5130 mL |
Rivastigmine metabolite 関連分類
HY-W020576 関連分類
Powered by Bioz